New drug KHN922 aims to shrink advanced tumors in early trial
Disease control
Not yet recruiting
This study tests a new drug, KHN922, in 276 adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants receive the drug intravenously and are monitored for side effects and …
Phase: PHASE1, PHASE2 • Sponsor: Chengdu Kanghong Biotech Co., Ltd. • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC